Cargando…

Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?

SIMPLE SUMMARY: The quantification of PD-L1 expression in tumor samples through the tumor proportion score (TPS) and the combined positive score (CPS) conditions provides access to anti-PD-1/PD-L1 immunotherapy in patients with various solids cancers. Reproducibility studies have shown very heteroge...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercier, Anaïs, Conan-Charlet, Virginie, Quintin-Roué, Isabelle, Doucet, Laurent, Marcorelles, Pascale, Uguen, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216272/
https://www.ncbi.nlm.nih.gov/pubmed/37345105
http://dx.doi.org/10.3390/cancers15102768
_version_ 1785048258509275136
author Mercier, Anaïs
Conan-Charlet, Virginie
Quintin-Roué, Isabelle
Doucet, Laurent
Marcorelles, Pascale
Uguen, Arnaud
author_facet Mercier, Anaïs
Conan-Charlet, Virginie
Quintin-Roué, Isabelle
Doucet, Laurent
Marcorelles, Pascale
Uguen, Arnaud
author_sort Mercier, Anaïs
collection PubMed
description SIMPLE SUMMARY: The quantification of PD-L1 expression in tumor samples through the tumor proportion score (TPS) and the combined positive score (CPS) conditions provides access to anti-PD-1/PD-L1 immunotherapy in patients with various solids cancers. Reproducibility studies have shown very heterogeneous inter- and intra-pathologist agreements, from poor to excellent ones, in TPS and CPS quantification. We studied the inter- and intra-pathologist agreements in TPS and CPS quantification comparing single PD-L1 immunohistochemistry (S-IHC) and double immunohistochemistry (D-IHC) combining PD-L1 staining and tumor nuclear markers, trying to improve the distinction between tumor cells and immune cells necessary to TPS and CPS calculations. Our study concluded in excellent (TPS) to good (CPS) inter- and intra-pathologist agreements with both S-IHC and D-IHC with slightly higher intraclass correlation coefficients using D-IHC. D-IHC could help the pathologists to quantify PD-L1 expression through TPS and CPS for subsequent therapeutic choices in patients with advanced cancers. ABSTRACT: We studied the pathologists’ agreements in quantifying PD-L1 expression through the tumor proportion score (TPS) and the combined positive score (CPS) using single PD-L1 immunohistochemistry (S-IHC) and double immunohistochemistry (D-IHC) combining PD-L1 staining and tumor cell markers. S-IHC and D-IHC were applied to 15 cancer samples to generate 60 digital IHC slides (30 whole slides images and 30 regions of interest of 1 mm(2)) for PD-L1 expression quantification using both TPS and CPS, twice by four pathologists. Agreements were estimated calculating intraclass correlation coefficients (ICC). Both S-IHC and D-IHC slides analyses resulted in excellent (for TPS, ICC > 0.9) to good (for CPS, ICC > 0.75) inter- and intra-pathologist agreements with slightly higher ICC with D-IHC than with S-IHC. S-IHC resulted in higher TPS and CPS than D-IHC (+5.6 and +6.1 mean differences, respectively). High reproducibility in the quantification of PD-L1 expression is attainable using S-IHC and D-IHC.
format Online
Article
Text
id pubmed-10216272
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102162722023-05-27 Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists? Mercier, Anaïs Conan-Charlet, Virginie Quintin-Roué, Isabelle Doucet, Laurent Marcorelles, Pascale Uguen, Arnaud Cancers (Basel) Article SIMPLE SUMMARY: The quantification of PD-L1 expression in tumor samples through the tumor proportion score (TPS) and the combined positive score (CPS) conditions provides access to anti-PD-1/PD-L1 immunotherapy in patients with various solids cancers. Reproducibility studies have shown very heterogeneous inter- and intra-pathologist agreements, from poor to excellent ones, in TPS and CPS quantification. We studied the inter- and intra-pathologist agreements in TPS and CPS quantification comparing single PD-L1 immunohistochemistry (S-IHC) and double immunohistochemistry (D-IHC) combining PD-L1 staining and tumor nuclear markers, trying to improve the distinction between tumor cells and immune cells necessary to TPS and CPS calculations. Our study concluded in excellent (TPS) to good (CPS) inter- and intra-pathologist agreements with both S-IHC and D-IHC with slightly higher intraclass correlation coefficients using D-IHC. D-IHC could help the pathologists to quantify PD-L1 expression through TPS and CPS for subsequent therapeutic choices in patients with advanced cancers. ABSTRACT: We studied the pathologists’ agreements in quantifying PD-L1 expression through the tumor proportion score (TPS) and the combined positive score (CPS) using single PD-L1 immunohistochemistry (S-IHC) and double immunohistochemistry (D-IHC) combining PD-L1 staining and tumor cell markers. S-IHC and D-IHC were applied to 15 cancer samples to generate 60 digital IHC slides (30 whole slides images and 30 regions of interest of 1 mm(2)) for PD-L1 expression quantification using both TPS and CPS, twice by four pathologists. Agreements were estimated calculating intraclass correlation coefficients (ICC). Both S-IHC and D-IHC slides analyses resulted in excellent (for TPS, ICC > 0.9) to good (for CPS, ICC > 0.75) inter- and intra-pathologist agreements with slightly higher ICC with D-IHC than with S-IHC. S-IHC resulted in higher TPS and CPS than D-IHC (+5.6 and +6.1 mean differences, respectively). High reproducibility in the quantification of PD-L1 expression is attainable using S-IHC and D-IHC. MDPI 2023-05-16 /pmc/articles/PMC10216272/ /pubmed/37345105 http://dx.doi.org/10.3390/cancers15102768 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mercier, Anaïs
Conan-Charlet, Virginie
Quintin-Roué, Isabelle
Doucet, Laurent
Marcorelles, Pascale
Uguen, Arnaud
Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title_full Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title_fullStr Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title_full_unstemmed Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title_short Reproducibility in PD-L1 Immunohistochemistry Quantification through the Tumor Proportion Score and the Combined Positive Score: Could Dual Immunostaining Help Pathologists?
title_sort reproducibility in pd-l1 immunohistochemistry quantification through the tumor proportion score and the combined positive score: could dual immunostaining help pathologists?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216272/
https://www.ncbi.nlm.nih.gov/pubmed/37345105
http://dx.doi.org/10.3390/cancers15102768
work_keys_str_mv AT mercieranais reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists
AT conancharletvirginie reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists
AT quintinroueisabelle reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists
AT doucetlaurent reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists
AT marcorellespascale reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists
AT uguenarnaud reproducibilityinpdl1immunohistochemistryquantificationthroughthetumorproportionscoreandthecombinedpositivescorecoulddualimmunostaininghelppathologists